Tech Company Financing Transactions
Beacon Therapeutics Funding Round
Beacon Therapeutics, based in Alachua, raised $75 million in funding from Goldman Sachs, Advent Life Sciences and Forbion Capital Partners.
Transaction Overview
Company Name
Announced On
1/8/2026
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series C
Investors
Goldman Sachs (Lead Investor) (Colin Walsh)
Proceeds Purpose
The new funds will be used to complete the development of lead program, laru-zova, a potential best-in-class gene therapy currently being investigated for the treatment of patients with XLRP, and progress commercialization plans.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
14193 NW 119th Terrace, Suite #10
Alachua, FL 32615
USA
Alachua, FL 32615
USA
Phone
Website
Email Address
Overview
Beacon Therapeutics is an ophthalmic gene therapy company founded to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. Our established scientific foundation combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP) with two innovative and differentiated preclinical programs for prevalent and rare blinding diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Fellows
Chief Medical Officer
Nadia Waheed
Chief Scientific Officer
Abraham Scaria
Vice President
Eduardo Jacobo
Browse more venture capital transactions:
Prev: 1/8/2026: Nocion Therapeutics venture capital transaction
Next: 1/8/2026: Obita venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs